Trump unveils 100 percent tariff on drugs to push for pharmaceutical deals

Lead

US President Donald Trump has signed an executive order that could impose tariffs of up to 100% on patented pharmaceuticals imported into the United States, following through on a long-standing threat to pressure drugmakers to shift production to American soil. The order, signed on Thursday, is part of a broader push to lower drug costs and secure domestic supply chains.

Under the new measure, companies that move manufacturing to the US could see the tariff reduced to 20%, according to reports from Al Jazeera and ABC Australia. Firms that strike a "most favoured nation" pricing deal with the administration and are actively building US facilities could face zero tariffs, as detailed by a senior administration official who briefed reporters.

Coverage Comparison

Coverage of the announcement varied in focus. ABC Australia emphasised the order's implications for Australian exporters, noting that pharmaceuticals are among the country's top exports to the US, worth about $1.6 billion in 2023-24. The Australian outlet highlighted that Melbourne-based manufacturer CSL has been investing heavily in US manufacturing to mitigate tariff risks.

Al Jazeera provided a broader international perspective, reporting that the European Union, Japan, South Korea, and Switzerland will face a 15% tariff on patented pharmaceuticals, while the UK secured a 10% rate that could drop to zero under future trade agreements. The outlet also noted the administration's claim that domestic production is vital for national security.

The Guardian focused on Australia's response, quoting Health Minister Mark Butler as saying the government would not cave in to pressure to dismantle consumer price protections under the Pharmaceutical Benefits Scheme (PBS). The Guardian reported that Australia exports about $2 billion worth of drugs to the US annually, with CSL's blood plasma products comprising the bulk.

Key Claims

Tariff Structure and Timelines

Large pharmaceutical companies will have 120 days to announce plans to avoid the new tariff, while smaller companies are given 180 days, according to multiple sources. Al Jazeera reported that companies without a pricing deal but with US construction plans would initially face a 20% tariff, escalating to 100% over four years.

The tariff is being implemented under a section of trade law designed to protect national security, making it unaffected by the Supreme Court ruling that invalidated Trump's earlier "Liberation Day" tariffs, as ABC Australia noted.

Deals and Exemptions

The Trump administration has negotiated 17 pricing deals with major drugmakers, 13 of which have been signed, according to a senior administration official quoted by Al Jazeera. These deals are said to be worth hundreds of billions of dollars in manufacturing moved to the US.

Generic drugs are expected to be exempt from the tariffs, as reported by The Guardian. Companies like CSL, which produces blood plasma products, are also expected to receive exemptions, per the same report.

Australia's Stance

Australia's Health Minister Mark Butler stated that the government would not negotiate on the fundamentals of the PBS, which ensures lower prices for prescription holders. "We keep sending this clearest of possible messages to the US because we know they get the big drug companies in their ear trying to unpick the PBS," Butler told reporters, as quoted by The Guardian.

Perspectives

US Administration

The White House frames the tariffs as necessary to secure the domestic supply of vital drugs in times of conflict or emergencies, such as a pandemic. A senior administration official argued that while the US innovates and holds patents, production has been outsourced abroad, leaving the country vulnerable.

Pharmaceutical Industry

Industry leaders have been in discussions with the administration, with 17 pricing deals already reached, according to the official. The reductions for companies that relocate or sign deals suggest a willingness to negotiate, though the impact on drug prices remains uncertain.

Australia and Other Countries

Australia's government has resisted pressure to alter its pricing scheme, while countries like the EU, Japan, South Korea, and Switzerland have accepted lower tariffs. The UK's separate deal underscores the varied responses to the US action, with some nations opting for negotiation and others holding firm.

Conclusion

The executive order represents a significant escalation in Trump's trade policy, with far-reaching implications for global pharmaceutical manufacturing and pricing. While the full impact remains to be seen, the move has already drawn clear lines: companies and countries must choose between compliance and potential tariffs. As the 120- and 180-day windows unfold, the industry will be watching closely to see which firms strike deals and how the tariffs reshape drug supply chains.